CONCORD, C.A.—VANTON RESEARCH LABORATORY, LLC (“VRL”) today announced the human clinical trial of an Investigational New Drug (IND) of its client. This new drug VRL developed is an injectable or infusible oncologic new chemical entity (NCE) formulated with VRL’s proprietary platform technology. VRL’s delivery system prolongs solution stability beyond 48 hours following hospital reconstitution and dilution, much longer than most oncologic infusion solutions that last no more than 4 to 6 hours. “This new formulation takes into account the molecular interplays among all ingredients and situates the infusion solution at its optimal physical state for the best stability in the hospital environment for these types of molecules” said Julie Chen, VRL’s Chief Operating Officer. “All our platform technologies are science based and technically proven. They are ready for different classes of pharmaceutical actives into appropriate dosage forms to maximize therapeutic needs, and that is VRL’s ultimate goal,” she further emphasized.
Vanton Research Laboratory, LLC is a privately owned contract research organization (CRO) and a specialty phama, focusing on development of non-conventional drug delivery systems. It provides a comprehensive range of fully integrated Pharmaceutical Development Services including pre-formulation, formulation, analytical development, and clinical manufacturing. In addition to CRO services, Vanton also develops in-house pipeline products for niche markets. The leading product is a subcutaneous Ropivacaine depot system using its proprietary molecular caging (MC) technology for post-operational pain management. Other specialty products focus on chronic disease treatment using its novel sustained released oral disintegrating tablet (ODT-SR) technology.
For more information about the company, please visit www.vantonlab.com
Vanton Research Laboratory, LLC
Ms. Julie M. Chen
Chief Operating Officer
Investor Relations: Ms. Carol Hafizi